A study conducted by Dr. Gilead Fortuna and Yuval Neev of the Samuel Neaman Institute shows that the rate of added value produced by TEVA is significantly higher than the industrial standard in Israel. Therefore the impact of reducing the production of Teva in Israel on the work force and the supporting industries and services industries, will be very large
In addition, a significant reduction of Teva size in Israel could discourage young companies from becoming larger independent industrial companies, and they might prefer to make an exit rather than growth.
